Current status of immunotherapy in acute myeloid leukemia
Acute myeloid leukemia (AML) is a rapidly progressive, poor prognosis malignant tumor caused by hematopoietic stem cells/progenitor cells. In recent years, there have been significant advances in basic and preclinical research on AML. Compared with traditional chemotherapy, hematopoietic stem cell t...
Main Author: | Li Wenrui |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2021-01-01
|
Series: | E3S Web of Conferences |
Online Access: | https://www.e3s-conferences.org/articles/e3sconf/pdf/2021/47/e3sconf_icepe2021_03025.pdf |
Similar Items
-
Immunotherapies for Acute Myeloid Leukemia
Published: (2020) -
Emerging Immunotherapy for Acute Myeloid Leukemia
by: Rikako Tabata, et al.
Published: (2021-02-01) -
The Important Role of Immunotherapies in Acute Myeloid Leukemia
by: Jochen Greiner
Published: (2019-11-01) -
Recent developments in immunotherapy of acute myeloid leukemia
by: Felix S. Lichtenegger, et al.
Published: (2017-07-01) -
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
by: Alessandro Isidori, et al.
Published: (2021-05-01)